- Home
- GF vs TLSA Comparison
GF vs TLSA Comparison
Compare GF & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GF
- TLSA
- Stock Information
- Founded
- GF 1990
- TLSA 2013
- Country
- GF Germany
- TLSA United Kingdom
- Employees
- GF N/A
- TLSA N/A
- Industry
- GF Investment Managers
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- GF Finance
- TLSA Health Care
- Exchange
- GF Nasdaq
- TLSA Nasdaq
- Market Cap
- GF 155.4M
- TLSA 175.3M
- IPO Year
- GF N/A
- TLSA 2000
- Fundamental
- Price
- GF $10.89
- TLSA $1.36
- Analyst Decision
- GF
- TLSA
- Analyst Count
- GF 0
- TLSA 0
- Target Price
- GF N/A
- TLSA N/A
- AVG Volume (30 Days)
- GF 28.1K
- TLSA 484.8K
- Earning Date
- GF 01-01-0001
- TLSA 05-27-2025
- Dividend Yield
- GF 0.82%
- TLSA N/A
- EPS Growth
- GF N/A
- TLSA N/A
- EPS
- GF N/A
- TLSA N/A
- Revenue
- GF N/A
- TLSA N/A
- Revenue This Year
- GF N/A
- TLSA N/A
- Revenue Next Year
- GF N/A
- TLSA N/A
- P/E Ratio
- GF N/A
- TLSA N/A
- Revenue Growth
- GF N/A
- TLSA N/A
- 52 Week Low
- GF $7.38
- TLSA $0.54
- 52 Week High
- GF $9.41
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- GF 65.82
- TLSA 51.81
- Support Level
- GF $10.82
- TLSA $1.22
- Resistance Level
- GF $11.00
- TLSA $1.78
- Average True Range (ATR)
- GF 0.12
- TLSA 0.19
- MACD
- GF -0.01
- TLSA -0.01
- Stochastic Oscillator
- GF 84.29
- TLSA 27.59
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.